ProBioGen announces Innovent as a new Partner signing License of GlymaxX® Technology
Berlin, Germany, January 11, 2022: ProBioGen today announced that Innovent Biologics, Inc. (1801.HK) has signed a multi-product license for ProBioGen's GlymaxX technology. Under..
Imvaq Therapeutics signs a Service and Commercial Product License to use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform
Berlin, Germany and New York, USA, January 6, 2022: ProBioGen AG is delighted to announce the execution of a service and commercial product license agreement with Imvaq..
ProBioGen's GlymaxX® Technology reaches Phase III Clinical Development
Berlin, December 17, 2021: ProBioGen AG, a leading technology developer and CDMO for cell line development through GMP manufacturing announces an important clinical milestone for..
ProBioGen's GlymaxX® Technology made it again into Clinical Phase I
Berlin, November 17, 2021: ProBioGen, a premier CDMO for cell line development through GMP manufacturing which has also developed innovative technologies, announced that another..
PEGS Europe 2021: ProBioGen's Presentation shows how the DirectedLuck™ Transposase System streamlines Cell Line Development
Barcelona, Spain, November 3, 2021: ProBioGen is delighted to announce that today, its Chief Scientific Officer Dr. Volker Sandig has presented at 13th annual PEGS Europe Protein..
ProBioGen’s DirectedLuck™ Transposase Licensed by TOP15 Global BioPharma Company
Berlin, Germany, September 28, 2021: ProBioGen today announced the closing of a DirectedLuck Transposase Technology research license agreement with another global biopharma..
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Nov 5, 2024
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
May 29, 2024
ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
Mar 27, 2024
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Mar 13, 2024
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
Sep 26, 2023
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
Apr 12, 2023
